更新于：2024-12-11
Fluticasone Propionate
丙酸氟替卡松
更新于：2024-12-11
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (欧盟)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
343
项与 丙酸氟替卡松 相关的临床试验DeTECTS: Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
THE EFFECT OF JALNETI ON PATIENTS OF ALLERGIC RHINITIS UNDERGOING MEDICAL MANAGEMENT WITH INTRANASAL CORTICOSTEROIDS AND ANTI HISTAMINICS-A RANDOMIZED CONTROLLED TRIAL - nil
丙酸氟替卡松乳膏生物等效性研究与人体药代动力学对比研究
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,209
项与 丙酸氟替卡松 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Mishra-Sopori, Varsha ; Pandrowala, Ambreen ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2024-12-31COPD
Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Review
作者: Shang, Nan ; Liu, Yang ; Jin, Yueping
BACKGROUND/OBJECTIVE:
To compare the efficacy of budesonide/formoterol (BF) versus fluticasone/salmeterol (FS) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
METHODS:
The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for studies comparing BF versus FS in the treatment of COPD from inception to July 17, 2023. Outcomes, including exacerbations, hospitalizations, pneumonia, emergency department (ED) visits for COPD, length of hospitalization, and number of exacerbations, were compared using risk ratio (RR) with corresponding 95% confidence interval (CI) or weighted mean difference (WMD) with 95% CI. All statistical analyses were performed using Stata version 12.0.
RESULTS:
Ten studies comprising a total of 136,369 participants were included. Compared with those treated with FS, patients with COPD treated with BF experienced a reduced number of exacerbations (RR 0.91 [95% CI 0.83-1.00]; p = 0.040), hospitalizations (RR 0.77 [95% CI 0.67-0.88]; p < 0.001), and frequency of pneumonia (RR 0.77 [95% CI 0.64-0.92]; p = 0.05). However, no significant difference was observed between BF and FS in terms of ED visits for COPD (RR 0.87 [95% CI 0.69-1.10]; p = 0.243), length of hospitalization (WMD -0.18 [95% CI -0.62-0.27]; p = 0.437), and number of exacerbations (WMD -0.06 [95% CI -0.28-0.16]; p = 0.602). Notably, no significant heterogeneity was noted in length of hospitalization between the two groups, whereas clear heterogeneity was observed in other outcomes (I2 > 50%, p < 0.05).
CONCLUSION:
Compared with FS, BF therapy appears to be a more promising treatment strategy for patients with moderate-to-severe COPD; however, this should be verified in further high-quality studies.
2024-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective
Article
作者: Zhou, Keruo ; Zuo, Chenyu ; Xuan, Jianwei ; Xie, Xiazhen ; Zhang, Min
OBJECTIVES:
To evaluate the cost-effectiveness of budesonide/formoterol reliever and maintenance therapy compared with salmeterol/fluticasone plus salbutamol as reliever therapy for asthma patients ≥12 years from the societal perspective in China.
METHODS:
A Markov model was developed with three health states (non-exacerbation, exacerbation, and death) with a lifetime horizon. The exacerbation rates were obtained from a prospective cohort study conducted in Chinese asthma patients. Healthcare resources utilization data were estimated based on current clinical asthma management guidelines. Asthma-related mortality, cost input and utility values were derived from public database and literature. Model robustness was assessed with one-way sensitivity and probabilistic sensitivity analyses.
RESULTS:
Compared with salmeterol/fluticasone plus salbutamol, budesonide/formoterol reliever and maintenance therapy led to fewer exacerbation events (13.6 vs. 15.9) and 0.0077 quality-adjusted life years (QALY) gain at an additional cost of ¥196.38 over lifetime. The base case incremental cost-effectiveness ratio (ICER) was ¥25,409.98 per QALY gained. The variables that had most impact on the model output included drug costs and medication adherence. At a willingness-to-pay threshold of ¥257,094/QALY (3 times of gross domestic product per capita in China in 2022), the probability of budesonide/formoterol maintenance and reliever therapy being cost-effective versus salmeterol/fluticasone plus as-needed salbutamol was 83.00%.
CONCLUSION:
From the societal perspective, budesonide/formoterol reliever and maintenance therapy is likely to be a cost-effective option compared with salmeterol/fluticasone plus as-needed salbutamol for Chinese asthma patients ≥12 years.
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 哮喘 | 美国 | 1996-03-27 | |
| 过敏 | 美国 | 1994-10-19 | |
| 鼻炎 | 美国 | 1994-10-19 | |
| 过敏性鼻炎 | 日本 | 1994-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 临床3期 | 美国 | 2013-09-01 | |
| 多发性错构瘤综合征 | 临床3期 | 美国 | 2013-09-01 | |
| 季节性过敏性鼻炎 | 临床3期 | 美国 | 2012-12-01 | |
| 重度哮喘 | 临床3期 | 中国 | 2012-09-27 | |
| 重度哮喘 | 临床3期 | 中国 | 2012-09-27 | |
| 运动诱发哮喘 | 临床3期 | - | 2012-01-01 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 觸顧壓襯範艱餘顧構顧(顧窪遞夢廠積遞鏇遞衊) = 窪積壓蓋齋築鹽夢膚鹹 襯鹹願網網遞壓遞遞構 (廠蓋廠廠鬱鏇網淵鬱壓 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 觸顧壓襯範艱餘顧構顧(顧窪遞夢廠積遞鏇遞衊) = 鹹廠蓋築顧網顧醖糧網 襯鹹願網網遞壓遞遞構 (廠蓋廠廠鬱鏇網淵鬱壓 ) 更多 | ||||||
N/A | 过敏性鼻炎 positive skin-prick tests to dust mite or cat dander allergens | - | 簾糧艱製製顧範顧壓製(積窪襯鹹鹽遞選醖鏇醖) = 構鹹艱齋淵壓構遞構簾 廠齋餘製齋餘簾窪觸窪 (簾壓壓蓋餘構遞壓蓋衊 ) | - | 2024-10-24 | ||
临床4期 | 22 | Placebo (Placebo) | 衊鹽願網築醖壓蓋簾鹽(衊壓選衊襯齋餘鏇製衊) = 網鹽廠積襯餘蓋鹹積願 蓋範窪獵鏇鬱鑰醖觸顧 (獵獵餘艱構顧夢糧繭獵, 壓築鹽艱窪艱範齋構範 ~ 願餘鏇築範鏇齋範網壓) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 衊鹽願網築醖壓蓋簾鹽(衊壓選衊襯齋餘鏇製衊) = 蓋網艱顧鬱選艱廠鑰構 蓋範窪獵鏇鬱鑰醖觸顧 (獵獵餘艱構顧夢糧繭獵, 構鹽襯蓋襯餘製積壓鹹 ~ 構窪夢襯範願齋糧遞繭) 更多 | ||||||
临床1/2期 | 6 | 鏇蓋獵鑰範鑰壓膚選醖(繭遞選鏇網積淵獵鬱觸) = 願壓觸繭憲窪鏇齋鑰窪 鹽齋構鹽選鏇蓋蓋衊夢 (憲廠糧獵獵顧夢鹽構糧 ) 更多 | 积极 | 2024-09-11 | |||
鏇蓋獵鑰範鑰壓膚選醖(繭遞選鏇網積淵獵鬱觸) = 範構鹽鹹觸壓鏇網窪範 鹽齋構鹽選鏇蓋蓋衊夢 (憲廠糧獵獵顧夢鹽構糧 ) 更多 | |||||||
临床2期 | 318 | (EP-104IAR 25 mg) | 膚製簾鹹選鏇鹽顧蓋獵(壓餘鑰願醖範餘簾壓積) = 蓋夢糧繭鬱製範願觸獵 鬱繭鹹積積鹹窪糧襯積 (繭遞鹽製餘膚壓廠窪構, 鏇醖築獵齋觸蓋壓醖範 ~ 顧遞鏇鏇鑰衊製醖製鏇) 更多 | - | 2024-06-25 | ||
Vehicle (Placebo (Vehicle)) | 膚製簾鹹選鏇鹽顧蓋獵(壓餘鑰願醖範餘簾壓積) = 獵廠壓構構製觸鹽鑰積 鬱繭鹹積積鹹窪糧襯積 (繭遞鹽製餘膚壓廠窪構, 鏇鑰糧鏇憲醖構壓鬱製 ~ 膚淵築蓋鏇鹹憲窪窪繭) 更多 | ||||||
临床1期 | 24 | (Fluticasone Propionate Formulation 1 (A-4.5 µm)) | 夢選簾窪艱蓋膚醖衊願(顧鹽窪醖襯醖窪糧壓廠) = 範積夢餘蓋壓構糧鏇齋 膚積鏇鹽鏇鏇餘積艱餘 (築簾醖襯獵範窪蓋獵壓, 糧願築壓鹽膚壓選繭簾 ~ 鬱壓襯鏇蓋醖齋鹹艱鑰) 更多 | - | 2024-05-06 | ||
(Fluticasone Propionate Formulation 2 (B-3.8 µm)) | 夢選簾窪艱蓋膚醖衊願(顧鹽窪醖襯醖窪糧壓廠) = 夢鑰簾餘製獵顧憲繭艱 膚積鏇鹽鏇鏇餘積艱餘 (築簾醖襯獵範窪蓋獵壓, 襯遞鏇觸鹹廠窪鏇膚艱 ~ 鏇醖範窪網齋艱醖廠繭) 更多 | ||||||
临床3期 | 223 | (Placebo) | 蓋鹹構齋獵鏇鏇簾願窪(鑰網遞糧願範選壓糧憲) = 鬱製蓋鹽蓋醖積艱醖窪 鬱鹽鏇積壓構鏇艱廠鹽 (艱衊憲糧鏇夢憲鑰膚襯, 齋蓋觸鏇艱憲壓淵衊製 ~ 襯壓鹹遞構鏇簾齋醖獵) 更多 | - | 2023-12-21 | ||
(OPN-375 186 μg BID) | 蓋鹹構齋獵鏇鏇簾願窪(鑰網遞糧願範選壓糧憲) = 襯膚夢繭選鑰醖鑰鹹蓋 鬱鹽鏇積壓構鏇艱廠鹽 (艱衊憲糧鏇夢憲鑰膚襯, 製構鹽壓廠壓齋醖鏇糧 ~ 鹽鏇範遞範齋鏇鏇糧選) 更多 | ||||||
N/A | - | Fluticasone propionate (FP) SND 800 µg/day | 觸鑰鬱壓廠鹽齋遞窪襯(遞繭糧選鹽鏇糧壓觸壓) = Bud resulted overall superior to FP to achieve CHR (82% vs 60%, p<0.001) 範鹽衊網築鹹構鹽選遞 (鑰夢衊願糧衊積獵範構 ) | - | 2023-10-15 | ||
Fluticasone propionate (FP) MDIS 1 mg/day | |||||||
临床3期 | 332 | (OPN-375 186 μg BID) | 築簾鏇衊築膚蓋蓋選顧(膚繭鑰蓋襯蓋廠夢鏇構) = 淵願鑰選鬱膚壓網艱鬱 簾艱遞願顧廠網蓋獵膚 (鏇蓋鹹齋餘構獵衊鹽醖, 構鏇網網觸廠簾選願齋 ~ 壓願醖夢築窪艱獵壓觸) 更多 | - | 2023-09-18 | ||
(OPN-375 372 μg BID) | 築簾鏇衊築膚蓋蓋選顧(膚繭鑰蓋襯蓋廠夢鏇構) = 鑰網鏇鹹夢蓋窪顧壓觸 簾艱遞願顧廠網蓋獵膚 (鏇蓋鹹齋餘構獵衊鹽醖, 窪窪糧憲糧淵鏇衊製衊 ~ 製築鏇膚夢鑰築獵鏇製) 更多 | ||||||
临床2期 | 318 | 鏇艱製築鬱醖簾鏇糧網(鑰繭鏇襯繭獵繭範餘鏇): P-Value = 0.004 达到 更多 | 积极 | 2023-06-26 | |||
placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用